NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Greenphire, LLC
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution - Greenphire’s eClinicalGPS now offers Single Sign-On (SSO) through Exostar’s identity and access management platform, critical to supporting the TransCelerate Shared Investigator Platform community - Exostar.com / Greenphire.com
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

 

NewswireToday - /newswire/ - Miami, FL, United States, 2017/01/24 - Greenphire’s eClinicalGPS now offers Single Sign-On (SSO) through Exostar’s identity and access management platform, critical to supporting the TransCelerate Shared Investigator Platform community - Exostar.com / Greenphire.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Summit for Clinical Operations Executives (SCOPE) - Greenphire, the global leader in clinical payment solutions, and Exostar, whose cloud-based solutions help companies mitigate risk and solve their identity and access challenges, today announced a partnership that facilitates the adoption, accessibility and use of clinical research site payment solutions. The partnership brings web-based Single Sign-On (SSO) functionality to Greenphire’s eClinicalGPS, creating seamless and secure access to the global clinical site payment platform.

TransCelerate BioPharma is a non-profit organization whose mission is to collaborate across the global biopharmaceutical R&D community to drive the efficient, effective and high-quality delivery of new medicines. TransCelerate established the Shared Investigator Platform (SIP) Initiative to deliver content and services to Investigator Sites via a single point of access for interaction with participating clinical trial sponsors. Exostar’s identity and access management platform serves as the gateway to SIP, verifying user credentials before granting SSO access to connected sponsor and third-party applications. By teaming with Exostar, Greenphire’s eClinicalGPS is now directly available with valid credentials throughout the TransCelerate SIP and Exostar life sciences communities.

“There is a great deal of administrative burden placed on a research site to support a clinical trial. Greenphire’s solutions are designed to reduce this burden and allow investigators and research staff to focus on supporting the trial, not tracking payments,” said Jim Murphy, CEO of Greenphire. “This collaboration with Exostar brings simplicity to the user experience, making it even easier to take advantage of our powerful payment solution.”

“As the industry looks to optimize the clinical experience for trial site staff and users by leveraging digital technology, access to assets across enterprise boundaries must be controlled, but painless and efficient,” said Kenny Kong, Exostar’s Director of Life Sciences and Health IT. “Together with Greenphire, we are delivering a compelling user experience where individuals throughout the clinical trial ecosystem can present a single trusted Exostar credential to seamlessly reach Greenphire’s robust trial payment functionality through TransCelerate’s Shared Investigator Platform.”

About Greenphire

Greenphire (greenphire.com) is the leader in global clinical trial payment solutions. Greenphire’s best-in-class solutions optimize clinical trial performance by simplifying and streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials.

About Exostar

Exostar (exostar.com), named a Cool Vendor for 2016 by Gartner, offers cloud-based solutions that help companies in highly-regulated industries mitigate risk and solve identity and access challenges. Nearly 125,000 organizations leverage Exostar to help them collaborate securely, efficiently, and compliantly with their partners and suppliers. By offering connect-once, single sign-on access, Exostar strengthens security, reduces expenditures, and raises productivity so customers can better meet contractual, regulatory, and time-to-market objectives.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Greenphire, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Press Office - Greenphire.com 
215-609-4378 / 215-609-4640 corporate[.]greenphire.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greenphire, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Greenphire, LLC / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
Veeva Widely Recognized for Leadership and Innovation in Support of Customers and Employees
Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management
Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments
PharmaEssentia Selects Veeva Data Cloud to Support Launch of Novel Therapy for Rare, Chronic Blood Cancers
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050 - A Novel Individualized Neoantigen Cancer Vaccine
DSM Plans New Production Site for Bovaer® in Dalry, Scotland
Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow, Inc.





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)